Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration
Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR-/-) mice at treatment dosa...
Saved in:
| Published in | PloS one Vol. 13; no. 10; p. e0206416 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
26.10.2018
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR-/-) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days. In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR-/- mouse infection model was investigated. IFNAR-/- mice were subcutaneously infected with SFTSV at a 1.0 × 10(6) 50% tissue culture infectious dose followed by twice daily administration of favipiravir, comprising a total dose of either 120 mg/kg/day or 200 mg/kg/day. The treatment was initiated either immediately post infection or at predesignated time points post infection. Neutralizing antibodies in the convalescent-phase mouse sera was examined by the pseudotyped VSV system. All mice treated with favipiravir at dosages of 120 mg/kg/day or 200 mg/kg/day survived when the treatment was initiated at no later than 4 days post infection. A decrease in body weight of mice was observed when the treatment was initiated at 3-4 days post infection. Furthermore, all control mice died. The body weight of mice did not decrease when treatment with favipiravir was initiated immediately post infection at dosages of 120 mg/kg/day and 200 mg/kg/day. Neutralizing antibodies were detected in the convalescent-phase mouse sera. Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR-/- mice infected with SFTSV was effective. |
|---|---|
| AbstractList | Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR-/-) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days. In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR-/- mouse infection model was investigated. IFNAR-/- mice were subcutaneously infected with SFTSV at a 1.0 × 10(6) 50% tissue culture infectious dose followed by twice daily administration of favipiravir, comprising a total dose of either 120 mg/kg/day or 200 mg/kg/day. The treatment was initiated either immediately post infection or at predesignated time points post infection. Neutralizing antibodies in the convalescent-phase mouse sera was examined by the pseudotyped VSV system. All mice treated with favipiravir at dosages of 120 mg/kg/day or 200 mg/kg/day survived when the treatment was initiated at no later than 4 days post infection. A decrease in body weight of mice was observed when the treatment was initiated at 3-4 days post infection. Furthermore, all control mice died. The body weight of mice did not decrease when treatment with favipiravir was initiated immediately post infection at dosages of 120 mg/kg/day and 200 mg/kg/day. Neutralizing antibodies were detected in the convalescent-phase mouse sera. Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR-/- mice infected with SFTSV was effective. Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR−/−) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days. In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR−/− mouse infection model was investigated. IFNAR−/− mice were subcutaneously infected with SFTSV at a 1.0 × 106 50% tissue culture infectious dose followed by twice daily administration of favipiravir, comprising a total dose of either 120 mg/kg/day or 200 mg/kg/day. The treatment was initiated either immediately post infection or at predesignated time points post infection. Neutralizing antibodies in the convalescent-phase mouse sera was examined by the pseudotyped VSV system. All mice treated with favipiravir at dosages of 120 mg/kg/day or 200 mg/kg/day survived when the treatment was initiated at no later than 4 days post infection. A decrease in body weight of mice was observed when the treatment was initiated at 3–4 days post infection. Furthermore, all control mice died. The body weight of mice did not decrease when treatment with favipiravir was initiated immediately post infection at dosages of 120 mg/kg/day and 200 mg/kg/day. Neutralizing antibodies were detected in the convalescent-phase mouse sera. Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR−/− mice infected with SFTSV was effective. Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR-/-) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days. In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR-/- mouse infection model was investigated. IFNAR-/- mice were subcutaneously infected with SFTSV at a 1.0 × 10(6) 50% tissue culture infectious dose followed by twice daily administration of favipiravir, comprising a total dose of either 120 mg/kg/day or 200 mg/kg/day. The treatment was initiated either immediately post infection or at predesignated time points post infection. Neutralizing antibodies in the convalescent-phase mouse sera was examined by the pseudotyped VSV system. All mice treated with favipiravir at dosages of 120 mg/kg/day or 200 mg/kg/day survived when the treatment was initiated at no later than 4 days post infection. A decrease in body weight of mice was observed when the treatment was initiated at 3-4 days post infection. Furthermore, all control mice died. The body weight of mice did not decrease when treatment with favipiravir was initiated immediately post infection at dosages of 120 mg/kg/day and 200 mg/kg/day. Neutralizing antibodies were detected in the convalescent-phase mouse sera. Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR-/- mice infected with SFTSV was effective.Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR-/-) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days. In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR-/- mouse infection model was investigated. IFNAR-/- mice were subcutaneously infected with SFTSV at a 1.0 × 10(6) 50% tissue culture infectious dose followed by twice daily administration of favipiravir, comprising a total dose of either 120 mg/kg/day or 200 mg/kg/day. The treatment was initiated either immediately post infection or at predesignated time points post infection. Neutralizing antibodies in the convalescent-phase mouse sera was examined by the pseudotyped VSV system. All mice treated with favipiravir at dosages of 120 mg/kg/day or 200 mg/kg/day survived when the treatment was initiated at no later than 4 days post infection. A decrease in body weight of mice was observed when the treatment was initiated at 3-4 days post infection. Furthermore, all control mice died. The body weight of mice did not decrease when treatment with favipiravir was initiated immediately post infection at dosages of 120 mg/kg/day and 200 mg/kg/day. Neutralizing antibodies were detected in the convalescent-phase mouse sera. Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR-/- mice infected with SFTSV was effective. Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR.sup.-/-) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days. In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR.sup.-/- mouse infection model was investigated. IFNAR.sup.-/- mice were subcutaneously infected with SFTSV at a 1.0 x 10.sup.6 50% tissue culture infectious dose followed by twice daily administration of favipiravir, comprising a total dose of either 120 mg/kg/day or 200 mg/kg/day. The treatment was initiated either immediately post infection or at predesignated time points post infection. Neutralizing antibodies in the convalescent-phase mouse sera was examined by the pseudotyped VSV system. All mice treated with favipiravir at dosages of 120 mg/kg/day or 200 mg/kg/day survived when the treatment was initiated at no later than 4 days post infection. A decrease in body weight of mice was observed when the treatment was initiated at 3-4 days post infection. Furthermore, all control mice died. The body weight of mice did not decrease when treatment with favipiravir was initiated immediately post infection at dosages of 120 mg/kg/day and 200 mg/kg/day. Neutralizing antibodies were detected in the convalescent-phase mouse sera. Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR.sup.-/- mice infected with SFTSV was effective. Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR −/− ) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days. In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR −/− mouse infection model was investigated. IFNAR −/− mice were subcutaneously infected with SFTSV at a 1.0 × 10 6 50% tissue culture infectious dose followed by twice daily administration of favipiravir, comprising a total dose of either 120 mg/kg/day or 200 mg/kg/day. The treatment was initiated either immediately post infection or at predesignated time points post infection. Neutralizing antibodies in the convalescent-phase mouse sera was examined by the pseudotyped VSV system. All mice treated with favipiravir at dosages of 120 mg/kg/day or 200 mg/kg/day survived when the treatment was initiated at no later than 4 days post infection. A decrease in body weight of mice was observed when the treatment was initiated at 3–4 days post infection. Furthermore, all control mice died. The body weight of mice did not decrease when treatment with favipiravir was initiated immediately post infection at dosages of 120 mg/kg/day and 200 mg/kg/day. Neutralizing antibodies were detected in the convalescent-phase mouse sera. Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR −/− mice infected with SFTSV was effective. |
| Audience | Academic |
| Author | Morikawa, Shigeru Taniguchi, Satoshi Shimojima, Masayuki Saijo, Masayuki Nakajima, Nozomi Furuta, Yousuke Fukuma, Aiko Fukushi, Shuetsu Komeno, Takashi Tani, Hideki Uda, Akihiko |
| AuthorAffiliation | University of Texas Medical Branch, UNITED STATES 2 Department of Virology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan 4 Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan 1 Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan 3 Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan |
| AuthorAffiliation_xml | – name: 1 Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan – name: 2 Department of Virology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan – name: 3 Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan – name: University of Texas Medical Branch, UNITED STATES – name: 4 Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan |
| Author_xml | – sequence: 1 givenname: Hideki orcidid: 0000-0002-6309-277X surname: Tani fullname: Tani, Hideki – sequence: 2 givenname: Takashi surname: Komeno fullname: Komeno, Takashi – sequence: 3 givenname: Aiko surname: Fukuma fullname: Fukuma, Aiko – sequence: 4 givenname: Shuetsu surname: Fukushi fullname: Fukushi, Shuetsu – sequence: 5 givenname: Satoshi surname: Taniguchi fullname: Taniguchi, Satoshi – sequence: 6 givenname: Masayuki surname: Shimojima fullname: Shimojima, Masayuki – sequence: 7 givenname: Akihiko surname: Uda fullname: Uda, Akihiko – sequence: 8 givenname: Shigeru surname: Morikawa fullname: Morikawa, Shigeru – sequence: 9 givenname: Nozomi surname: Nakajima fullname: Nakajima, Nozomi – sequence: 10 givenname: Yousuke surname: Furuta fullname: Furuta, Yousuke – sequence: 11 givenname: Masayuki orcidid: 0000-0001-5458-7298 surname: Saijo fullname: Saijo, Masayuki |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30365543$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tq3DAQhk1JaQ7tG5RWUCjtxW5lW5btXBRCegoEAm3aWzGWxmsFr7WR5LT7Un3GjpNNyYZQikEW42_-8fzS7Cc7gxswSZ6nfJ7mZfruwo1-gH6-ovCcZ1yKVD5K9tI6z2Yy4_nOnf1ush_CBedFXkn5JNnNeS6LQuR7ye_zDj2scIxWM2xb1DEw17IWruzKelo9gwXYIUQW8Ao9snZ6sZ82dix23i0bp9fRrXCwwMJ6MBRCRnljYHaYBK0baMeA9Rg76NnSjQFpNdgfsg8u4IwKWw16zUIcjcXARuqKOU8wmKUdbIgeJp2nyeMW-oDPNu-D5Punj-fHX2anZ59Pjo9OZ1rWWZwhVA2vK4GmqctcaN3KikNbFgbSCtKslLIguyrUooJCtwJbIfKq5mhE3lZNfpC8vNFd9S6ojdVBZWlWSCHJaiJObgjj4EKtvF2CXysHVl0HnF8o8GRqj4pTxdQ02piyFkKmkFUVtlw2otIGNJDW-021sVmi0ThQu_2W6PaXwXZq4a7UdLZ5WZLAm42Ad5cjhqiWNmjsexiQzJ7-W9acTr0m9NU99OHuNtQCqAE6Rkd19SSqjoqirkWW84qo-QMUPQaXVtO9bC3FtxLebiUQE_FXXMAYgjr59vX_2bMf2-zrO2yH0McuuH6crkzYBl_cdfqvxbcDQcDhDaC9C8Fjq7SN11ePWrO9Srmapu_WNDVNn9pMHyWLe8m3-v9M-wO42ziZ |
| CitedBy_id | crossref_primary_10_1016_j_antiviral_2020_104926 crossref_primary_10_1371_journal_ppat_1012101 crossref_primary_10_3389_fmed_2022_879982 crossref_primary_10_1016_j_celrep_2019_12_020 crossref_primary_10_1172_JCI129171 crossref_primary_10_1016_j_antiviral_2022_105479 crossref_primary_10_1016_j_antiviral_2022_105273 crossref_primary_10_1016_j_vetmic_2019_06_019 crossref_primary_10_1016_j_virol_2019_06_014 crossref_primary_10_3389_fphar_2025_1491150 crossref_primary_10_3389_fmicb_2021_772802 crossref_primary_10_1371_journal_pntd_0009103 crossref_primary_10_3389_fmicb_2021_797189 crossref_primary_10_1002_rmv_2039 crossref_primary_10_7883_yoken_JJID_2021_851 crossref_primary_10_1093_pnasnexus_pgac024 crossref_primary_10_1016_j_antiviral_2020_104993 crossref_primary_10_1007_s40121_022_00693_x crossref_primary_10_1016_j_antiviral_2022_105387 crossref_primary_10_1016_j_rmcr_2020_101200 crossref_primary_10_1080_21645515_2019_1633875 crossref_primary_10_1038_s41467_021_21992_w crossref_primary_10_3389_fphar_2021_735223 crossref_primary_10_1016_j_antiviral_2023_105582 crossref_primary_10_1111_nyas_15080 crossref_primary_10_3389_fphar_2020_01196 crossref_primary_10_2169_naika_110_1797 crossref_primary_10_3389_fmicb_2020_00150 |
| Cites_doi | 10.1371/journal.pntd.0002614 10.1093/cid/cit530 10.1016/j.antiviral.2018.03.003 10.2183/pjab.93.027 10.1016/j.micinf.2014.12.002 10.1016/j.antiviral.2014.02.014 10.1093/cid/ciw571 10.1128/mSphere.00061-15 10.1016/j.bcp.2014.11.008 10.1016/j.antiviral.2017.11.019 10.1093/infdis/jis472 10.1016/j.antiviral.2014.01.012 10.1016/S1473-3099(14)70718-2 10.1371/journal.pmed.1001967 10.3947/ic.2017.49.1.72 10.7883/yoken.67.423 10.1371/journal.pone.0080802 10.1128/JVI.00110-16 10.1371/journal.pntd.0002804 10.1093/infdis/jit603 10.1128/JCM.00742-14 10.1016/j.virol.2017.08.004 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 Public Library of Science 2018 Tani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 Tani et al 2018 Tani et al |
| Copyright_xml | – notice: COPYRIGHT 2018 Public Library of Science – notice: 2018 Tani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 Tani et al 2018 Tani et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0206416 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Agricultural Science Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Treatment of SFTSV infection with favipiravir |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2125646641 oai_doaj_org_article_0a121dbcdd794461a288ef06b48cdaca PMC6203377 A559942308 30365543 10_1371_journal_pone_0206416 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: ; grantid: JP18fk0108072 – fundername: ; grantid: JP15K08510 – fundername: ; grantid: H25-Shinko-Shitei-009 – fundername: ; grantid: JP18fk0108002 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c692t-ea8b0984edb9734ccf680af75da18a1276654168ec48a5cf4ef443890ed43f8b3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Feb 06 00:55:12 EST 2022 Wed Aug 27 01:28:39 EDT 2025 Thu Aug 21 18:05:53 EDT 2025 Fri Jul 11 01:32:38 EDT 2025 Fri Jul 25 10:31:03 EDT 2025 Tue Jun 17 22:04:46 EDT 2025 Tue Jun 10 21:03:04 EDT 2025 Fri Jun 27 05:59:09 EDT 2025 Fri Jun 27 05:28:57 EDT 2025 Thu May 22 21:24:09 EDT 2025 Wed Feb 19 02:37:02 EST 2025 Thu Apr 24 23:05:14 EDT 2025 Tue Jul 01 02:09:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-ea8b0984edb9734ccf680af75da18a1276654168ec48a5cf4ef443890ed43f8b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors declare no conflicts of interest in association with the present study. |
| ORCID | 0000-0002-6309-277X 0000-0001-5458-7298 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0206416 |
| PMID | 30365543 |
| PQID | 2125646641 |
| PQPubID | 1436336 |
| PageCount | e0206416 |
| ParticipantIDs | plos_journals_2125646641 doaj_primary_oai_doaj_org_article_0a121dbcdd794461a288ef06b48cdaca pubmedcentral_primary_oai_pubmedcentral_nih_gov_6203377 proquest_miscellaneous_2126903039 proquest_journals_2125646641 gale_infotracmisc_A559942308 gale_infotracacademiconefile_A559942308 gale_incontextgauss_ISR_A559942308 gale_incontextgauss_IOV_A559942308 gale_healthsolutions_A559942308 pubmed_primary_30365543 crossref_citationtrail_10_1371_journal_pone_0206416 crossref_primary_10_1371_journal_pone_0206416 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-10-26 |
| PublicationDateYYYYMMDD | 2018-10-26 |
| PublicationDate_xml | – month: 10 year: 2018 text: 2018-10-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2018 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | SJ Smither (ref22) 2014; 104 JR Spengler (ref24) 2018; 150 M Shimojima (ref7) 2014; 67 JB Westover (ref15) 2017; 511 BB Gowen (ref16) 2017 W Liu (ref10) 2013; 57 L Oestereich (ref23) 2014; 8 I Park (ref9) 2017; 49 L Oestereich (ref19) 2014; 105 BB Gowen (ref21) 2013; 7 XY Lei (ref2) 2015; 17 T Takahashi (ref3) 2014; 209 KH Kim (ref4) 2013; 19 Y Furuta (ref12) 2017; 93 Q Liu (ref1) 2014; 14 T Yoshikawa (ref18) 2014; 52 ZT Gai (ref6) 2012; 206 H Tani (ref17) 2016; 90 L Delang (ref11) 2018; 153 D Sissoko (ref14) 2016; 13 CQ Bai (ref20) 2016; 63 E De Clercq (ref13) 2015; 93 H Tani (ref8) 2016; 1 B Deng (ref5) 2013; 8 |
| References_xml | – volume: 7 start-page: e2614 issue: 12 year: 2013 ident: ref21 article-title: Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0002614 – volume: 57 start-page: 1292 issue: 9 year: 2013 ident: ref10 article-title: Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome publication-title: Clin Infect Dis doi: 10.1093/cid/cit530 – volume: 153 start-page: 85 year: 2018 ident: ref11 article-title: Favipiravir as a potential countermeasure against neglected and emerging RNA viruses publication-title: Antiviral Res doi: 10.1016/j.antiviral.2018.03.003 – volume: 93 start-page: 449 issue: 7 year: 2017 ident: ref12 article-title: Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase publication-title: Proc Jpn Acad Ser B Phys Biol Sci doi: 10.2183/pjab.93.027 – volume: 17 start-page: 149 issue: 2 year: 2015 ident: ref2 article-title: Severe fever with thrombocytopenia syndrome and its pathogen SFTSV publication-title: Microbes Infect doi: 10.1016/j.micinf.2014.12.002 – volume: 105 start-page: 17 year: 2014 ident: ref19 article-title: Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model publication-title: Antiviral Res doi: 10.1016/j.antiviral.2014.02.014 – volume: 63 start-page: 1288 issue: 10 year: 2016 ident: ref20 article-title: Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014 publication-title: Clin Infect Dis doi: 10.1093/cid/ciw571 – volume: 1 issue: 1 year: 2016 ident: ref8 article-title: Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus publication-title: mSphere doi: 10.1128/mSphere.00061-15 – volume: 93 start-page: 1 issue: 1 year: 2015 ident: ref13 article-title: Ebola virus (EBOV) infection: Therapeutic strategies publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2014.11.008 – volume: 150 start-page: 137 year: 2018 ident: ref24 article-title: Second International Conference on Crimean-Congo Hemorrhagic Fever publication-title: Antiviral Res doi: 10.1016/j.antiviral.2017.11.019 – volume: 19 start-page: 1892 issue: 11 year: 2013 ident: ref4 article-title: Severe fever with thrombocytopenia syndrome, South Korea, 2012 publication-title: Emerg Infect Dis – volume: 206 start-page: 1095 issue: 7 year: 2012 ident: ref6 article-title: Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients publication-title: J Infect Dis doi: 10.1093/infdis/jis472 – start-page: 91 year: 2017 ident: ref16 article-title: Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir publication-title: J Virol – volume: 104 start-page: 153 year: 2014 ident: ref22 article-title: Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model publication-title: Antiviral Res doi: 10.1016/j.antiviral.2014.01.012 – volume: 14 start-page: 763 issue: 8 year: 2014 ident: ref1 article-title: Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70718-2 – volume: 13 start-page: e1001967 issue: 3 year: 2016 ident: ref14 article-title: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea publication-title: PLoS Med doi: 10.1371/journal.pmed.1001967 – volume: 49 start-page: 72 issue: 1 year: 2017 ident: ref9 article-title: Two Treatment Cases of Severe Fever and Thrombocytopenia Syndrome with Oral Ribavirin and Plasma Exchange publication-title: Infect Chemother doi: 10.3947/ic.2017.49.1.72 – volume: 67 start-page: 423 issue: 6 year: 2014 ident: ref7 article-title: Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro publication-title: Jpn J Infect Dis doi: 10.7883/yoken.67.423 – volume: 8 start-page: e80802 issue: 11 year: 2013 ident: ref5 article-title: Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast China publication-title: PLoS One doi: 10.1371/journal.pone.0080802 – volume: 90 start-page: 5292 issue: 11 year: 2016 ident: ref17 article-title: Characterization of Glycoprotein-Mediated Entry of Severe Fever with Thrombocytopenia Syndrome Virus publication-title: J Virol doi: 10.1128/JVI.00110-16 – volume: 8 start-page: e2804 issue: 5 year: 2014 ident: ref23 article-title: Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0002804 – volume: 209 start-page: 816 issue: 6 year: 2014 ident: ref3 article-title: The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan publication-title: J Infect Dis doi: 10.1093/infdis/jit603 – volume: 52 start-page: 3325 issue: 9 year: 2014 ident: ref18 article-title: Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load publication-title: J Clin Microbiol doi: 10.1128/JCM.00742-14 – volume: 511 start-page: 175 year: 2017 ident: ref15 article-title: Heartland virus infection in hamsters deficient in type I interferon signaling: Protracted disease course ameliorated by favipiravir publication-title: Virology doi: 10.1016/j.virol.2017.08.004 |
| SSID | ssj0053866 |
| Score | 2.4370825 |
| Snippet | Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a viral hemorrhagic fever with a high case fatality rate. Favipiravir was... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0206416 |
| SubjectTerms | Administration, Oral Amides - administration & dosage Amides - pharmacology Amides - therapeutic use Analysis Animals Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antiviral agents Biology and Life Sciences Body weight Cercopithecus aethiops Disease Models, Animal Dose-response relationship (Biochemistry) Dose-Response Relationship, Drug Drug dosages Drug therapy Ebola virus Fatalities Fever Hemorrhage Hemorrhagic fever Infections Infectious diseases Influenza Interferon Laboratories Medicine and Health Sciences Mice Mortality Neutralizing Oral administration People and Places Peritoneum Phlebotomus Fever - drug therapy Phlebovirus - drug effects Phlebovirus - immunology Phlebovirus - physiology Pyrazines - administration & dosage Pyrazines - pharmacology Pyrazines - therapeutic use Research and Analysis Methods RNA polymerase Rodents Thrombocytopenia Tissue culture Vero Cells Virology Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELXQnrggyldDCwwICTikTWLHcbiVj6pwAAla1FvkOHa7UklWm91K_VP8RmYSJ2xQpXLgtKv1ZJXMjMcvyfg9xl5aXkaVq_JQOW1CIa0KVVLaMBNprHPNk9x1bJ9f5NGJ-Hyanm5IfVFPWE8P3DtuP9JxElelqSrMHCFjnShlXSRLoUylTQeNcM0bbqb6GoyzWEq_UY5n8b6Py96iqe0eAiQpSN98YyHq-PrHqjxbXDTtdZDz787JjaXo8C674zEkHPTnvsVu2foe2_KztIXXnkr6zX326_jP9irwrRvQOHD6ck5v2C_nS9Bneo4YEXCJtEsLjj6AHs8CSSj8LBtztSKNrbmGgd4A8Lh1C0MjV43fQANmwDmeFj1LsNAp7LyFD01rQ0s0FdpcQds3LcIaPQREDQB6wt37gJ0cfjx-fxR6hYbQyDxZhVarMsqVsFWZZ1wY46SKtMvSSscKA5eRtnEslTVC6dQ4YZ0gufXIVoI7VfKHbFZjTLYZVCQ8oxBuKmK0F1lexrlQrsSShGnEk4DxIVyF8fTlpKJxUXTv5DK8jem9X1CQCx_kgIXjUYuevuMG-3eUCaMtkW93P2BKFj4li5tSMmDPKI-KfifrWEKKA2J3Q_gaqYC96CyIgKOmDp8zvW7b4tPXH_9g9P3bxOiVN3INugOD2e-qwGsiYq-J5e7EEsuImQxvU9YPXmkLxDSpJPGBGI8cZsL1w8_HYfpT6tqrLeYa2cgcVxGeB-xRP3FGzxJ0QijLA5ZNptTE9dORen7e8Z_LJOI8yx7_j1jtsNsIgTuG40TustlqubZPEGauyqddRfkNSMaBlQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZguXBBlFdTChiEBBzSJrHXcbig8iiFA0jQot4iP7crlWTZ7Fbqn-I3MpM4KUEVcMoqHkfJvNcef0PIU8d0Yr0tYumViblwMpaZdnHOp6kqFMsK36J9fhIHR_zj8fQ4LLg1oayy94mto7a1wTXyXXCxU4FY6OmrxY8Yu0bh7mpooXGVXEsh0mBJl9x_33tisGUhwnE5lqe7QTo7i7pyO5AmwbPEKBy1qP2Db54sTuvmssTzz_rJ3wLS_k1yI2SSdK8T_Qa54qpbZCPYakOfB0DpF7fJz8OLQ1Y0FHDQ2lOvzua4z342X1I1U3PIFCkESrd01OOF4iItxUYK33VtzlfYaWuuaA9yQGHeuqF9OVcFv6iioAcn8Fq4ouBo22fnJX1bNy52CFahzDltutJFugYOUQQIoGqE4HuHHO2_O3xzEIc-DbERRbaKnZI6KSR3Vhc548Z4IRPl86lVqVRplmOH41RIZ7hUU-O58xybrifOcualZnfJpAKZbBJqsf2MhKRTIq49zwudFlx6DY4JlIllEWG9uEoTQMyxl8Zp2e7M5fBnpuN-iUIug5AjEg-zFh2Ixz_oX6MmDLQIwd3eqJezMlh0mcCXpVYba8GlcZGqTErnE6G5NFYZFZFHqEdld551cCTlHmK8QRKbyIg8aSkQhqPCOp-ZWjdN-eHzt_8g-vplRPQsEPka2AHC7M5WwDchvNeIcntECc7EjIY3Uet7rjTlhdnBzN4SLh9-PAzjQ7F2r3Kga0gjCoglrIjIvc5wBs5iAgUJLYtIPjKpEevHI9X8pEVBF1nCWJ5v_f217pPrkOK2CMaZ2CaT1XLtHkAaudIPW1_xC-trd_E priority: 102 providerName: ProQuest |
| Title | Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30365543 https://www.proquest.com/docview/2125646641 https://www.proquest.com/docview/2126903039 https://pubmed.ncbi.nlm.nih.gov/PMC6203377 https://doaj.org/article/0a121dbcdd794461a288ef06b48cdaca http://dx.doi.org/10.1371/journal.pone.0206416 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LbxMxELba9MIFUV5NKcEgJOCw1T4c24uEUFsSChIFlQbltvJ67TRS2A3ZpCIXfhK_kZl9waLwuDhRPF7F4xn7W3v8DSGPTRC7iU1CR1qlHcaNdKQfG0ewvqdCFfihLdg-z_jpiL0d98dbpM7ZWikw3_hqh_mkRovZ4dcv65fg8C-KrA3CqxsdzrPUHAL84QAytskOrE0Ccxq8Y825Anh3cXqJqMXhvhtUl-n-9JTWYlVw-jczd2c-y_JNsPT36MpflqvhDXK9wpn0qDSMXbJl0ptkt_LknD6t6Kaf3SLfL35ewaJVeAfNLLXqaoqn8FfTBVUTNQUcSWEZNQtDLX5Q3MKlmGbhc5zp9RL1NlW0pkCg0G6V0zrYK4VvVFGwkkv4W7jfYGiRhec5fZXlxjFIZaH0muZlYCNdgYYo0gdQ1eL3vU1Gw8HFyalTZXFwNA_9pWOUjN1QMpPEoQiY1pZLV1nRT5QnlecLzH_scWk0k6qvLTOWYUp21yQssDIO7pBOCmOyR2iCyWkkQFKJrPdMhLEXMmljmLbA1AK_S4J6uCJdUZxjpo1ZVJzbCXjVKbUf4SBH1SB3idO0mpcUH_-QP0ZLaGSRoLv4IVtMosrfIxd65iWxThKY8Bj3lC-lsS6PmdSJ0qpLHqAdReVt12aaiY6QAQ4griu75FEhgSQdKUYBTdQqz6M37z_9h9DH85bQk0rIZqAOGMzy5gX0Ccm_WpIHLUmYanSreg-tvtZKHgHu6XNMUOBBy9oTNlc_bKrxoRjZlxqwNZThIaw0Qdgld0vHaTSL8ArgbtAlouVSLdW3a9LpZcGRjs4dCLH_9w7dI9cAABf8xj4_IJ3lYmXuA8hcxj2yLcYCSnniYTl83SM7x4OzD-e9YtumV8wrWH4b_AC7m4W3 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGeYAXxPhaYDCDQMBDtiR2HQcJocEoLRtDYh3aW3Acu6s0ktK0Q_2n9jdyl4-OoAl42VOj-hI5vvPPF_vud4Q8NSzxUptGrrRKu1wY6cogMW7Iu76KFAsiW7J97ov-If941D1aIWdNLgyGVTaYWAJ1mmvcI98CiO0K5EL330x-uFg1Ck9XmxIalVnsmsVP-GQrXg92QL_PgqD3fviu79ZVBVwtomDmGiUTL5LcpEkUMq61FdJTNuymypfKD0Ksx-sLaTSXqqstN5ZjiXDPpJxZmTB47hVylTNYyTEzvfehQX7ADiHq9DwW-lu1NWxO8sxsglsGfRet5a-sErBcCzqTk7y4yNH9M17ztwWwd5PcqD1Xul2Z2ipZMdktslpjQ0Ff1ATWL2-Ts-F5UhetA0ZobqlVp2M81z8dT6kaqTF4phQWZjM11OIPxU1hioUbvie5XsywstdY0YZUgcJ984I24WMZXFFFwe6OoVu4g2FoWdfnFd3JC-MaJMdQekGLKlSSzmGEKBISUNViDL5DDi9Fg3dJJwOdrBGaYrkbCU6uRB59HkaJH3FpEwBCMF4WOIQ16op1TZqOtTtO4vIkMISPp2r0Y1RyXCvZIe7yrklFGvIP-bdoCUtZpPwu_8ino7hGkNiDN_PTRKcpQCgXvgqkNNYTCZc6VVo5ZAPtKK7yZ5fAFW8jpxw4zZ50yJNSAmk_MowrGql5UcSDz1__Q-jgS0voeS1kcxgOUGaVywHvhHRiLcn1liSAl241r6HVN6NSxOfTHO5sZsLFzY-XzfhQjBXMDNgayogI1i4WOeReNXGWI4sOGzjQzCFha0q1hr7dko2PS9Z1EXiMheH9v3drg1zrDz_txXuD_d0H5Dq41yV7ciDWSWc2nZuH4MLOkkclblDy7bKB6hezZrU7 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGkRAviPFvgcEMAgEPWZPYdRwkhMZKtTE0EGxob8Fx7K7SSErTDvVL8QH4dNzl3wiagJc9NaovUXx3_vlin39HyGPDEi-1aeRKq7TLhZGuDBLjhnzgq0ixILIl2-e-2Dnkb48GRyvkZ3MWBtMqG0wsgTrNNa6R9wFiBwK50P2-rdMiPgxHr6bfXKwghTutTTmNykX2zPI7fL4VL3eHYOsnQTB6c7C949YVBlwtomDuGiUTL5LcpEkUMq61FdJTNhykypfKD0KszesLaTSXaqAtN5ZjuXDPpJxZmTB47iVyOWShxDEmt9v0EsARIeqjeiz0-7VnbE7zzGxCiAb9EJ2psKwY0M4LvelJXpwX9P6Zu_nbZDi6Tq7VUSzdqtxulayY7AZZrXGioM9qMuvnN8mPg7MDXrROHqG5pVadTnCP_3Qyo2qsJhClUpikzcxQiz8UF4gpFnH4muR6OccqXxNFG4IFCvctCtqkkmVwRRUFHzyG18LVDEPLGj8v6DAvjGuQKEPpJS2qtEm6AA1RJCegqsMefIscXogFb5NeBjZZIzTF0jcSAl6JnPo8jBI_4tImAIrgyCxwCGvMFeuaQB3reJzE5a5gCB9SlfZjNHJcG9khbnvXtCIQ-Yf8a_SEVhbpv8s_8tk4rtEk9qBnfproNAU45cJXgZTGeiLhUqdKK4dsoB_F1VnaFsTiLeSXgwDakw55VEogBUiGg2msFkUR777__B9Cnz52hJ7WQjYHdYAxq3Md0CekFutIrnckAch0p3kNvb7RShGfDXm4sxkJ5zc_bJvxoZg3mBnwNZQREcxjLHLInWrgtJrF4A2CaeaQsDOkOqrvtmST45KBXQQeY2F49--vtUGuAETF73b39-6RqxBpl0TKgVgnvflsYe5DNDtPHpSwQcmXi8apX3SquTw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+effects+of+favipiravir+against+severe+fever+with+thrombocytopenia+syndrome+virus+infection+in+a+lethal+mouse+model%3A+Dose-efficacy+studies+upon+oral+administration&rft.jtitle=PloS+one&rft.au=Tani%2C+Hideki&rft.au=Komeno%2C+Takashi&rft.au=Fukuma%2C+Aiko&rft.au=Fukushi%2C+Shuetsu&rft.date=2018-10-26&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=13&rft.issue=10&rft.spage=e0206416&rft_id=info:doi/10.1371%2Fjournal.pone.0206416&rft.externalDocID=A559942308 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |